[{"id":"922afab2-cb5b-4268-bf08-2403143bd7d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03931291","created_at":"2021-01-18T19:21:56.829Z","updated_at":"2024-07-02T16:35:07.650Z","phase":"Phase 2","brief_title":"APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant","source_id_and_acronym":"NCT03931291","lead_sponsor":"Aprea Therapeutics","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • eprenetapopt (APR-246)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 09/16/2019","start_date":" 09/16/2019","primary_txt":" Primary completion: 08/27/2021","primary_completion_date":" 08/27/2021","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2024-04-25"},{"id":"6e75b447-a0b9-4163-b3df-401e5d3d0a2e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03745716","created_at":"2021-01-18T18:20:44.648Z","updated_at":"2024-07-02T16:35:16.953Z","phase":"Phase 3","brief_title":"APR-246 \u0026 Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)","source_id_and_acronym":"NCT03745716","lead_sponsor":"Aprea Therapeutics","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • eprenetapopt (APR-246)"],"overall_status":"Completed","enrollment":" Enrollment 154","initiation":"Initiation: 01/11/2019","start_date":" 01/11/2019","primary_txt":" Primary completion: 11/27/2020","primary_completion_date":" 11/27/2020","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2024-02-29"},{"id":"0453689a-e657-4f9b-880f-0548f8fcf597","acronym":"","url":"https://clinicaltrials.gov/study/NCT04383938","created_at":"2021-01-18T21:10:03.406Z","updated_at":"2024-07-02T16:36:09.407Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies","source_id_and_acronym":"NCT04383938","lead_sponsor":"Aprea Therapeutics","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • eprenetapopt (APR-246)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 06/25/2020","start_date":" 06/25/2020","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 04/30/2022","study_completion_date":" 04/30/2022","last_update_posted":"2022-06-03"},{"id":"6160affe-41bc-4a57-bb71-a5426702805e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04990778","created_at":"2021-08-04T13:53:08.284Z","updated_at":"2024-07-02T16:36:15.692Z","phase":"Phase 2","brief_title":"Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma","source_id_and_acronym":"NCT04990778","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CCND1 • NOTCH2 • BIRC3 • NSD2","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation","tags":["CCND1 • NOTCH2 • BIRC3 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion • BIRC3 mutation • CCND1 overexpression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • eprenetapopt (APR-246)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 03/24/2023","study_completion_date":" 03/24/2023","last_update_posted":"2022-03-10"},{"id":"c0aae5a2-d214-4204-8770-3603ac0b210b","acronym":"MCC-18973","url":"https://clinicaltrials.gov/study/NCT03072043","created_at":"2021-01-18T15:08:04.521Z","updated_at":"2024-07-02T16:36:18.077Z","phase":"Phase 1b/2","brief_title":"Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms","source_id_and_acronym":"NCT03072043 - MCC-18973","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • Chr del(5q)","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • eprenetapopt (APR-246)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 11/15/2019","primary_completion_date":" 11/15/2019","study_txt":" Completion: 12/08/2021","study_completion_date":" 12/08/2021","last_update_posted":"2022-01-24"},{"id":"c32498cf-e1cd-4565-9b63-7e05239f3e7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03588078","created_at":"2021-01-18T17:38:49.785Z","updated_at":"2024-07-02T16:36:50.681Z","phase":"Phase 1b/2","brief_title":"Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine","source_id_and_acronym":"NCT03588078","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • eprenetapopt (APR-246)"],"overall_status":"Unknown status","enrollment":" Enrollment 53","initiation":"Initiation: 09/15/2018","start_date":" 09/15/2018","primary_txt":" Primary completion: 05/01/2020","primary_completion_date":" 05/01/2020","study_txt":" Completion: 05/15/2021","study_completion_date":" 05/15/2021","last_update_posted":"2020-01-30"}]